INTRODUCTION
Schizophrenia is characterized by profound disturbances in cognition, emotion, and social functioning. Catechol-Omethyl transferase (COMT) is the important enzyme for the metabolism of monoamines, which play important part in the pathogenesis of schizophrenia. COMT exists in high and low activity forms. The low activity form was found to be an amino acid substitution , which reduces the thermostability of the enzyme. This genetic polymorphism has been reported to be associated with schizophrenia and its associated clinical features (Li et al., 1996) . Shifman et al. (2002) reported a highly significant association between schizophrenia and a COMT haplotype in a large case-control sample. This haplotype included two noncoding single-nucleotide polymorphisms (SNPs) at either end of the COMT gene in addition to the valine-methionine (Val0Met) polymorphism. Bray et al. (2003) showed that COMT variants other than the Val0Met change are of functional importance to the human brain and that the haplotype implicated in schizophrenia susceptibility is likely to exert its effect, either directly or indirectly, by down-regulating COMT gene expression. However, little is known about the impact of such COMT variants upon the clinical manifestations and neurocognitive functions in patients with schizophrenia. Given the role of COMT alleles in physiology of prefrontal cognition and that the COMT gene variants are susceptible to schizophrenia (Egan et al., 2001) , we examined the specific clinical manifestations and neurocognitive profile of the patients with the identified COMT SNP rs165599 genotypes in a group of Chinese patients with schizophrenia.
MATERIALS AND METHODS
All patients met the DSM-IV (American Psychiatric Association, 1994) criteria of schizophrenia. Consensus diagnosis was made independently by two authors of the present study (EFCC, RYLC) by face-to-face interview using the Structured Clinical Interview for DSM-IV. All patients were taking conventional antipsychotic medication together with, in some cases, anticholinergic medication (benzhexol in all subjects). Patients with a history of physical illness involving the central nervous system, substance and0or alcohol abuse were excluded.
Patients genomic DNA was collected by standard method. The primers were designed by Primer3 program basic on the human genomic sequence from the public databases (National Institute of Health, 2004) . The sequences were: 59-CATTCAAAGCTCCCCTTGAC-39 and 59GGGAGTA GGGAAGGAGATGC-39. PCR was performed by using 100ng genomic DNA, 1x buffer, 1.5mM MgCl 2 , 0.2mM dNTPs, 0.25mM of each primer and 1U Taq (ABgene). Running conditions consists 35 cycles of 948C denaturing for 1 min, 568C annealing for 1 min and 728C extension for another 1 min. The PCR product (301bp) was then digested by the restriction enzyme MspI (New England BioLab). The A allele gives fragment of 301bp, while the G allele gives fragments of 166 and 135bp. The DNA fragments were detected by standard electrophoresis method. Perfect agreement (100%) on the genotyping processing was established between two laboratory technicians on the same sample.
Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) . The details of the complete procedure for each test are reported elsewhere (Chan et al., 2001; Halperin et al., 1991) . Background cognition was assessed with the Wechsler Adult Intelligence Test-III Scale (WAIS-III; Wechsler, 1997a).
Sustained attention was assessed by the Continuous Performance Test (Halperin et al., 1991) . Verbal and visual memory was assessed by the Logical Memory Test and Visual Reproduction Test from the Wechsler Memory Scale-III (WMS-III; Wechsler, 1997b) . Working memory was assessed by the Letter-Number Span Test (Gold et al., 1997) and 2-back test (Callicott et al., 1998) . Executive function was assessed by verbal fluency and the Stroop Test.
The university and the corresponding hospital ethics committees approved the research plan and the recruitment procedure of the subjects with schizophrenia. Informed consent was obtained from all the subjects prior to the testing session and blood taking in accordance with the Declaration of Helsinki.
SPSS for window version 11.0 was used for statistical analysis. We computed a standardized score (z score) with the normative data from our laboratory. Multiple univariate analysis of covariance (ANCOVA) controlling for age, intellectual functioning, medication and duration of illness would be made whenever appropriate. Another set of nonparametric test of Kruskal-Wallis H Test would also be conducted to check with the consistency of the results. Statistical significance was considered to be attained at p , .05.
RESULTS
A total of 36 patients (31 men, 5 women) were recruited and completed the full set of neurocognitive tests. The demographics of the sample are summarized in Table 1 . No significant differences were found among the groups in terms of education level, gender proportion, and diagnosis.
Multiple univariate ANCOVA controlling for age, duration of illness and medication dosage was conducted. Significant difference was found in negative symptoms [F(2,33) 5 4.4, p 5 0.026; 
DISCUSSION
The present study identified a differential pattern of clinical and neurocognitive profiles in patients with different COMT SNP rs165599 genotypes. The findings are summarized as follows:
1. Patients with COMT SNP G0G genotype exhibited the most severe negative symptoms as compared with those with COMT SNP A0A.
2. General impairments were observed in different subgroups of COMT SNP genotypes. Memory impairments and prefrontal executive function impairments were more pronounced in patients with COMT SNP G0G genotype.
COMT SNP rs165599 is a SNP with recent interest. It has not been widely studied. From the molecular point of view, it is at the downstream position of the COMT gene. There was evidence of the presence of this SNP transcript in human brain. This SNP (G0G) was found to be overrepresented in schizophrenia and also demonstrated to have reduction in COMT expression (Bray et al., 2003) . Thus it is speculated that this SNP polymorphism (or other nearby polymorphism in linkage disequilibrium) may involve in COMT gene regulation rendering susceptibility of schizophrenia and its associated clinical and neurocognitive impairment. The present study provides the first preliminary data on the impact of the COMT SNP rs165599 genotypes upon the clinical manifestations and neurocognitive performance in a group of Chinese patients with schizophrenia. Further 
